In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


iRhythm: Reinventing Arrhythmia Monitoring

Executive Summary

There has been a tendency in the health care products industries to design products that serve the maximum number of patients, in order to create the biggest markets. In pursuit of that all inclusive goal, medical device companies have often overengineered products, adding features - and costs - not necessary for the majority of patients. This has been the case in the field of arrhythmia monitoring. By challenging previous assumptions about arrhythmia monitoring, iRhythm believes it's developed a device that improves the diagnostic efficiency and ultimately the economics of arrhythmia care.

You may also be interested in...

Arrhythmia Monitoring: The Challenges Of Detecting AF In Cryptogenic Stroke

Innovation in arrhythmia monitoring technologies, as well as new research showing how these devices may improve arrhythmia diagnosis and management, particularly in cryptogenic stroke patients, will help drive growth in the market for outpatient ambulatory cardiac monitoring devices, which is valued at approximately $1.5 billion in the US alone.

Digital Health Briefs: Google Visits CDRH; IBM Watson Business; ZioPatch Data

CDRH hosts meet-and-greet with Google X staffers. IBM creates Watson business division. iRhythm reports favorable data for its ZioPatch arrhythmia monitor. More digital health briefs.

California HealthCare Funds Medtech Businesses For Social Ends

The CHCF Health Innovation Fund is authorized to provide up to $3 million in debt or convertible equity to health care companies that meet the private non-profit foundation’s goals of increasing access to care for low-income patients or reducing costs. Most deals fall in the $250,000 to $1 million range.

Related Content

Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts